Valuation: Atrion Corporation

Market Cap 81Cr 69Cr 65Cr 59Cr 111.45Cr 7.74TCr 112.92Cr 766.5Cr 298.91Cr 3.89TCr 303.94Cr 297.32Cr 13TCr P/E 2022
28.6x
P/E 2023 34.4x
Enterprise Value 80Cr 69Cr 64Cr 59Cr 110.62Cr 7.69TCr 112.09Cr 760.8Cr 296.69Cr 3.86TCr 301.68Cr 295.11Cr 13TCr EV / Sales 2022
5.27x
EV / Sales 2023 3.9x
Free-Float
50.88%
Yield 2022
1.47%
Yield 2023 2.3%
3 years 274.98
Extreme 274.98
503.24
5 years 274.98
Extreme 274.98
805.62
10 years 274.98
Extreme 274.98
948.03
Manager TitleAgeSince
Corporate Secretary 53 21/08/2024
Director TitleAgeSince
Director/Board Member 53 21/08/2024
Date Insider Type Main position Quantity % Market Cap.
21/08/24 Issuer sale

Director

2,991 0.1699%
21/08/24 Issuer sale

Chief Executive Officer

98,614 5.6032%
21/08/24 Issuer sale

Director

499 0.0284%
Change 5-day change 1-year change 3-year change Capi.($)
+0.06%-.--%-.--%-3.11% 81Cr
+2.19%+4.84%-12.03%+10.95% 20TCr
+1.14%+2.28%+0.69%+11.56% 12TCr
+1.06%+1.34%+8.69%+78.91% 6.07TCr
+0.38%-5.34%+29.65%+55.94% 5.24TCr
+2.33%+4.69%-3.84%-30.71% 5.23TCr
+2.35%+2.89%+12.25%-11.53% 3.48TCr
+5.16%-4.14% - - 3.01TCr
-0.20%+1.05%+42.46%-10.17% 2.48TCr
+0.91%-1.05%-1.35%+24.70% 2.38TCr
Average +1.54%+0.25%+8.50%+14.06% 6.01TCr
Weighted average by Cap. +1.73%+1.90%+1.72%+16.87%

Financials

2022 2023
Net sales 18Cr 16Cr 15Cr 13Cr 25Cr 1.76TCr 26Cr 173.77Cr 68Cr 882.01Cr 69Cr 67Cr 2.92TCr 17Cr 15Cr 14Cr 12Cr 23Cr 1.62TCr 24Cr 160.34Cr 63Cr 813.85Cr 64Cr 62Cr 2.69TCr
Net income 3.5Cr 3Cr 2.81Cr 2.57Cr 4.82Cr 334.95Cr 4.88Cr 33Cr 13Cr 168.26Cr 13Cr 13Cr 556.54Cr 1.94Cr 1.66Cr 1.56Cr 1.42Cr 2.67Cr 185.72Cr 2.71Cr 18Cr 7.17Cr 93Cr 7.29Cr 7.13Cr 308.59Cr
Net Debt -2.52Cr -2.16Cr -2.02Cr -1.85Cr -3.47Cr -241.22Cr -3.52Cr -24Cr -9.31Cr -121.17Cr -9.47Cr -9.26Cr -400.79Cr -60.16L -51.53L -48.22L -44.14L -82.83L -58Cr -83.93L -5.7Cr -2.22Cr -29Cr -2.26Cr -2.21Cr -96Cr
Logo Atrion Corporation
Atrion Corporation develops and manufactures products, primarily for medical applications. The Company's medical products are used in a number of fields including fluid delivery, cardiovascular, and ophthalmic applications. It has developed a variety of proprietary valves designed to precisely fill, hold, and release and/or remove controlled amounts of fluids, including blood and drugs, or gasses on demand for use in areas such as intubation, intravenous, catheter, and other applications in fields including anesthesia and oncology. The core of its cardiovascular products is its Myocardial Protection System, a technology that is the only open-heart surgery system that delivers to the heart essential fluids and medications, mixes critical drugs, and controls temperature, pressure, and other important variables. The Company also manufactures a line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults.
Employees
712
  1. Stock Market
  2. Stocks
  3. ATRI Stock